FDA NME Tally: Spring Thaw Brings Three March Approvals
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA closed the first quarter of 2003 with three new molecular entity approvals, all in March.
You may also be interested in...
MGI Palonosetron Study Shows Superiority To GSK Zofran; User Fee In July
A pivotal study comparing MGI Pharma’s 5-HT3 antagonist palonosetron to GlaxoSmithKline’s market leader Zofran shows superior efficacy for palonosetron in prevention of chemotherapy-induced nausea and vomiting.
New Drug Approvals In 2003 Could Include Four HIV Agents
FDA’s new molecular entity approval totals for 2003 could feature as many as four novel HIV agents.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011